Meningiomas

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See related separate articles Brain Tumours in Children and Brain Tumours in Adults.

Meningiomas are mostly benign tumours which arise from the dura mater and are usually slow-growing. Meningiomas usually form well-circumscribed lesions but, rarely can be more diffuse, eg when they grow next to the sphenoid ridge and are called 'meningioma en plaque'. Meningiomas occur either intracranially or within the spinal canal.[1] Meningiomas can be graded in various ways, eg site of origin, encroachment of surrounding tissues and histological grading. The most common system used is the World Health Organization (WHO) classification:[2]

  • Grade I (generally benign): meningothelial, psammomatous, secretory, fibroblastic, angiomatous, lymphoplasmacyte-rich, transitional, microcystic, metaplastic
  • Grade II (there is a higher rate of recurrence after surgery, especially if a resection is incomplete): clear-cell, chordoid, atypical. Chordoid type has been associated with Castleman's disease (an uncommon lymphoproliferative disorder).
  • Grade III (anaplastic): papillary (rare and mostly seen in children), rhabdoid and anaplastic. Grade III meningiomas are malignant with a high rate of local invasion, recurrence and metastases.
  • They are the most common benign intracranial tumours and account for up to 13-26% of primary intracranial tumours.
  • Incidence is 6 per 100,000 (highest after 50 years of age).
  • Female to male ratio of 2:1.
  • 2-3% of the population have asymptomatic meningiomas and 8% have multiple meningiomas.

NEW - log your activity

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »
  • Aetiology is not known and most cases are sporadic.[2]
  • Some are increased in the presence of certain genetic disorders, eg loss of chromosome 22 and presence of neurofibromatosis type 2.[2][4]
  • Other risk factors include cranial irradiation, head injury and breast cancer (although causality not determined).[3]
  • Skull vault.
  • Skull base, eg sphenoid wing and petrous ridge.
  • Sites of dural reflection, eg falx cerebri and tentorium cerebelli.
  • Optic nerve sheath.
  • Choroid plexus.
  • Spine (rarely).
  • Outside the craniospinal axis (very rarely), eg the ear, temporal bone and foot.
  • Proliferation markers provide information on likelihood of recurrence.
  • For example, MIB-1 and Ki67 are found in higher levels of tumours that are likely to recur.[3][5]
  • However, further work is needed to clarify the role of proliferation markers and prognosis.
  • Meningiomas can also express progesterone receptors.[6]
  • Higher levels of progesterone receptors have been reported to be associated with a lower frequency of recurrence and a better prognosis.
  • More than 70% of meningiomas express somatostatin receptors which can be used with radiological imaging, especially when looking for local recurrence.[3][7]

Meningiomas present as a space-occupying lesion (see link for separate article):

Other rare presentations include:

  • Meningiomas near the sella turcica may produce panhypopituitarism.
  • Spinal meningiomas may cause Brown-Séquard's Syndrome (see link for separate article).

This is as for other space-occupying lesions. Meningiomas can be discovered incidentally when patients are investigated for other conditions. Other lesions which may also affect the dura mater include:

  • Imaging - MRI is superior to CT scanning as it shows the dural origin. Meningiomas are well-defined, extra-axial lesions. They may show central cystic degeneration and oedema of nearby white matter.
  • Endovascular angiography allows preoperative assessment of the blood supply of the tumour and its proximity to vital vascular structures.[1]
  • Biopsy - stereotactic biopsy via a skull burr-hole or open exploration (craniotomy).

Management will depend on the clinical presentation, age of the patient, site of the tumour and size of the tumour. For example, an elderly patient with multiple comorbidities who is discovered incidentally to have a small, asymptomatic meningioma, can be managed conservatively. This usually consists of yearly MRI scans for 3 years and then just clinical follow-up if nothing new has developed.[3]

Endovascular embolisation

  • This involves embolisation of the blood supply to the meningioma, eg coil or glue applied endovascularly to the meningeal artery.[8]
  • This is usually performed before surgical removal, as it reduces the amount of blood loss.[9]
  • It has also been performed as the primary therapy in those unsuitable for surgery.
  • Embolisation usually causes necrosis of the meningioma, which can cause some histological doubt when specimens are examined postoperatively.[3]

Surgical removal

  • The tumour and its dural base are removed.
  • Total excision is the aim but this is not always possible, eg close neural tissue or en plaque meningiomas.
  • Surgery may be complicated by invasion into local structures, eg parasagittal tumours invading into the cerebral dural sinus.
  • Stereotactic radiosurgery can provide excellent local tumour control.[1]
  • Preoperative and postoperative corticosteroids significantly reduce mortality and morbidity rates associated with surgical resection. Antiepileptic drugs should be started preoperatively in supratentorial surgery and continued postoperatively for at least 3 months.[1]

Radiotherapy

  • Radiotherapy is used in the following:[1]
    • Incomplete resection.
    • Following recurrence of meningioma.
    • High-grade meningiomas with atypia or anaplasia on histology.
  • In these clinical scenarios the use of radiotherapy is associated with a better outcome. For example, in one study stereotactic radiosurgery was associated with better tumour control (approximately 10%) and fewer complications.[10] However, a recent paper has shed some doubt on how useful radiotherapy is in meningiomas.[11]
  • Stereotactic application of radiotherapy has further benefits compared with traditional radiotherapy. This includes less damage to undiseased tissue and better 5-year control rates.[3][12][13]
  • Radiotherapy is successful and may be used as the primary therapy for tumours, especially inaccessible meningiomas, eg optic nerve lesions.[3]

Chemotherapy and molecular agents

  • Chemotherapy has so far shown disappointing results and has been reserved for when surgery and radiotherapy have failed to control the disease.[1]
  • Chemotherapeutic regimens involving hydroxyurea have been used but with little success.[14][15]
  • Other drugs studied include temozolomide, RU-486 and interferon alfa, which have also shown disappointing results.[1]
  • More novel molecular targets are being researched.[16][17]
  • Atypical and anaplastic types of meningiomas can rarely metastasise.
  • Completely resected meningiomas usually have an excellent prognosis.[1] The 5-year survival for typical meningiomas is more than 80%; however, this falls to below 60% in malignant and atypical meningiomas.[15]

Further reading & references

  1. Haddad G et al; Meningioma, Medscape, Nov 2011
  2. Riemenschneider MJ, Perry A, Reifenberger G; Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006 Dec;5(12):1045-54.
  3. Whittle IR, Smith C, Navoo P, et al; Meningiomas. Lancet. 2004 May 8;363(9420):1535-43.
  4. Simon M, Bostrom JP, Hartmann C; Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery. 2007 May;60(5):787-98; discussion 787-98.
  5. Carvalho LH, Smirnov I, Baia GS, et al; Molecular signatures define two main classes of meningiomas. Mol Cancer. 2007 Oct 15;6:64.
  6. Omulecka A, Papierz W, Nawrocka-Kunecka A, et al; Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol. 2006;44(2):111-5.
  7. Durand A, Champier J, Jouvet A, et al; Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008 Sep-Oct;27(5):334-45.
  8. Qureshi AI; Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet. 2004 Mar 6;363(9411):804-13.
  9. Rodiek SO, Stolzle A, Lumenta ChB; Preoperative embolization of intracranial meningiomas with Embosphere microspheres. Minim Invasive Neurosurg. 2004 Oct;47(5):299-305.
  10. Buckner JC, Brown PD, O'Neill BP, et al; Central nervous system tumors. Mayo Clin Proc. 2007 Oct;82(10):1271-86.
  11. Marcus HJ, Price SJ, Wilby M, et al; Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg. 2008 Aug;22(4):520-8.
  12. Elia AE, Shih HA, Loeffler JS; Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus. 2007;23(4):E5.
  13. Kondziolka D, Lunsford LD, Flickinger JC; The application of stereotactic radiosurgery to disorders of the brain. Neurosurgery. 2008 Feb;62 Suppl 2:707-19; discussion 719-20.
  14. Modha A, Gutin PH; Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50.
  15. Marosi C, Hassler M, Roessler K, et al; Meningioma. Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71. Epub 2008 Mar 14.
  16. Wen PY, Drappatz J; Novel therapies for meningiomas. Expert Rev Neurother. 2006 Oct;6(10):1447-64.
  17. Norden AD, Drappatz J, Wen PY; Targeted drug therapy for meningiomas. Neurosurg Focus. 2007;23(4):E12.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Gurvinder Rull
Current Version:
Last Checked:
20/04/2011
Document ID:
9165 (v2)
© EMIS